- Leaky gut — formally called intestinal hyperpermeability — occurs when tight junction proteins break down, allowing toxins and undigested particles to enter the bloodstream.
- Research links impaired gut barrier function to IBS, IBD, type 1 diabetes, and celiac disease (PMID 39193076).
- Human milk oligosaccharides (HMOs) have been shown to reduce intestinal permeability, upregulate barrier-sealing proteins like claudin-8, and lower inflammatory markers like IL-6 (PMID 32933181).
- Lactoferrin enhances occludin expression and supports intestinal cell proliferation — directly fortifying the gut lining (PMID 37376017).
- kēpos combines kpHMO™ — its proprietary HMO ingredient — with effera™ recombinant human lactoferrin to support gut barrier integrity from two complementary angles.
You've probably heard someone say their doctor dismissed "leaky gut" as a wellness myth. And you've also probably seen it blamed for everything from brain fog to autoimmune disease on social media. The truth, as usual, is somewhere in the middle — and the science is far more interesting than either extreme suggests.
Intestinal permeability is real. It is measurable. And there is now compelling evidence that targeting it with the right bioactives — specifically HMOs and lactoferrin — may be one of the most effective strategies for supporting a healthier gut lining.
Here's what the research actually says.
What Actually Happens When Your Gut "Leaks"?
Your intestinal lining is a single layer of epithelial cells — roughly the surface area of a tennis court — held together by protein complexes called tight junctions. These junctions, made up of proteins like claudins, occludin, and zonula occludens (ZO-1), act like locks between cells. They allow nutrients, water, and beneficial compounds to pass through while keeping bacteria, toxins, and undigested food particles out of the bloodstream.
When those tight junctions are disrupted — by inflammation, dysbiosis, stress, or other insults — the seals break. Harmful particles can slip between cells and enter systemic circulation. This is intestinal hyperpermeability: the clinical reality behind the colloquial term "leaky gut."
A 2024 review published in Gastroenterology & Hepatology by Lacy et al. puts it plainly: the evidence links impaired intestinal barrier function directly to IBS, IBD, and type 1 diabetes, with tight junction proteins like claudins and occludin at the center of the mechanism (PMID 39193076). This is not fringe science — it's gastroenterology consensus.
What Causes Intestinal Permeability?
The gut barrier is surprisingly vulnerable. A 2023 review in Molecules identified the primary disruptors (PMID 36677677):
- Dysbiosis — An imbalance in gut bacteria that alters tight junction regulation and activates inflammatory cascades
- Antibiotics and NSAIDs — Broad-spectrum antibiotics deplete beneficial bacteria; NSAIDs directly damage gut mucosa
- Chronic stress — Stress hormones like corticotropin-releasing factor (CRF) increase paracellular permeability and are linked to visceral hypersensitivity
- Alcohol — Dissolves intestinal mucosal lipids and suppresses beneficial microbiota, reducing barrier hydrophobicity
- Western diet — High sugar, low fiber, and excess omega-6 fats are associated with dysbiosis and increased permeability
What's striking is that many of these causes are compounding. Stress can worsen dysbiosis; dysbiosis can fuel inflammation; inflammation disrupts tight junctions; and disrupted tight junctions let more inflammatory triggers into the bloodstream. It's a cycle — and one that's very hard to break with a single-ingredient approach.
What Conditions Are Linked to Leaky Gut?
The associations are well-documented. IBS patients show significantly lower levels of ZO-1 and occludin in intestinal tissue, along with elevated basal TNF-α, IL-1β, and IL-6 in serum — all markers of barrier dysfunction and chronic low-grade inflammation.
IBD patients show altered claudin expression (decreased claudin-1, -4, -7, and occludin in ulcerative colitis; decreased claudin-3, -5, and -8 in Crohn's disease). Type 1 diabetes shows impaired intestinal barrier function that may precede disease onset. Celiac disease triggers massive zonulin-mediated permeability in response to gliadin. And in patients with chronic heart failure, studies have measured a 35% increase in small bowel permeability and a 210% increase in large bowel permeability compared to healthy controls.
These aren't distant correlations. They represent a mechanism that's increasingly recognized as central to how systemic inflammation gets started and sustained.
Can You Actually Fix a Leaky Gut?
Yes — with important nuance. You cannot "cure" intestinal permeability with a single supplement. But the research is clear that specific bioactives can meaningfully support barrier repair, reduce permeability, and rebalance the microbial environment that tight junctions depend on.
The most evidence-backed approach involves two categories of intervention: reducing dysbiosis and inflammation, and directly reinforcing tight junction proteins. That's where HMOs and lactoferrin come in — and why their combination is uniquely powerful.
How HMOs Support Gut Barrier Repair
Human milk oligosaccharides aren't just prebiotics. They have direct effects on the gut epithelium that go well beyond feeding bifidobacteria.
A landmark study published in Nutrients by Šuligoj et al. demonstrated this using adult gut models including the SHIME® simulator, Caco2 cell monolayers, and human colon organoid-on-chips (PMID 32933181). After HMO fermentation by adult gut microbiota, the resulting metabolites significantly reduced paracellular permeability in Caco2 cells, upregulated the tight junction gene claudin-8, and reduced inflammatory IL-6 production. In the gut-on-chips (derived from real human colonic biopsies), claudin-5 was significantly upregulated across all three colon regions — proximal, transverse, and distal — following HMO treatment.
This is direct evidence that HMOs don't just reshape the microbiome — they actively support the structural integrity of the gut lining.
A 2024 study in Frontiers in Immunology by Boll et al. added another dimension: under active inflammatory conditions — simulated by TNF-α and IFN-β exposure — intestinal barrier integrity (measured by TEER) declined significantly without HMOs, but was maintained and stabilized in the presence of HMOs (PMID 38510254). Fucosylated and neutral HMOs were particularly effective. This matters: the gut barrier is most vulnerable precisely when it's inflamed, and HMOs may provide a protective shield exactly when one is needed most.
This is why kpHMO™ — the proprietary human milk bioactive ingredient designed and owned exclusively by kēpos, formulated to best match the oligosaccharide composition found in real breast milk — covers all neutral, fucosylated, and sialylated bases. Unlike supplements built around a single HMO, kpHMO™ is engineered to mirror the full oligosaccharide diversity of human milk, providing the spectrum of HMO structures shown in the research to collectively support gut barrier integrity. Explore kēpos →
Why effera™ Lactoferrin Is a Gut Barrier Game-Changer
Lactoferrin — a glycoprotein found in human milk — has its own independent and powerful effects on the gut lining. A comprehensive 2023 review in Pharmaceutics by Conesa et al. summarized the mechanisms clearly: lactoferrin promotes intestinal cell proliferation, enhances occludin expression (one of the primary tight junction proteins), and actively modulates the gut microbiota in favor of beneficial bacteria (PMID 37376017).
Occludin is the gatekeeper of tight junction sealing. When it's expressed at healthy levels, the locks between epithelial cells remain tight. Lactoferrin's ability to upregulate occludin expression makes it a direct structural ally for gut barrier repair — not just an indirect one via microbiome modulation.
kēpos features effera™ — recombinant human lactoferrin (rhLF), produced via precision fermentation to have an amino acid sequence identical to the lactoferrin found in human breast milk. This matters for gut health because human lactoferrin and bovine lactoferrin are not equivalent.
A 2026 randomized, double-blind, controlled trial published in the Journal of Dietary Supplements compared effera® to bovine lactoferrin in 66 healthy adults over 28 days (DOI: 10.1080/19390211.2026.2673021). The results were striking: effera® maintained microbial diversity and community structure while supporting beneficial taxa including Lachnospira, Paraprevotella, and Faecalibacterium — known producers of butyrate and short-chain fatty acids that fuel intestinal cell health. Bovine lactoferrin, by contrast, was associated with significant shifts in beta-diversity, suggesting it disrupts community structure rather than preserving it.
The combination of kpHMO™ and effera™ in kēpos creates a dual-mechanism approach: HMOs repair tight junction proteins and feed protective bifidobacteria, while human lactoferrin upregulates occludin and maintains the microbial ecosystem needed for long-term barrier health.
The Bottom Line: Yes, You Can Support a Healthier Gut Barrier
Leaky gut is not a myth — and it's not hopeless. It's a measurable physiological state that responds to targeted nutritional intervention. The strongest evidence points to bioactives that can simultaneously reduce dysbiosis, lower intestinal inflammation, and directly reinforce tight junction proteins.
HMOs and human lactoferrin are two of the most promising compounds ever studied for this purpose. Together, in kēpos, they represent a next-generation approach to gut health that goes beyond probiotics and fiber — directly addressing the structural integrity of the gut lining at the level of the science.
If you've tried probiotics and still feel bloated, gassy, or off — this is where the research points next. Try kēpos →
Frequently Asked Questions
Is leaky gut a real medical condition?
Intestinal hyperpermeability — the clinical term — is real and measurable. Research published in Gastroenterology & Hepatology (2024) confirms associations between impaired gut barrier function and IBS, IBD, and type 1 diabetes. The term "leaky gut syndrome" is informal, but the underlying physiology is well-documented (PMID 39193076).
What are the main signs of increased intestinal permeability?
Common associations include bloating, food sensitivities, chronic fatigue, brain fog, and digestive discomfort. However, because these symptoms are nonspecific, they can reflect many conditions. The most reliable test is the lactulose/mannitol test, which directly measures paracellular permeability in the small bowel.
Can HMOs help with leaky gut?
Research in adult gut models shows that HMOs significantly reduce intestinal permeability, upregulate tight junction proteins like claudin-8 and claudin-5, and reduce inflammatory cytokines like IL-6. Under simulated inflammatory conditions, HMOs helped maintain gut barrier integrity when untreated controls showed significant decline (PMID 32933181, PMID 38510254).
What does lactoferrin do for gut health?
Lactoferrin may support gut health by promoting intestinal cell proliferation, enhancing the expression of tight junction proteins like occludin, and modulating the gut microbiome toward beneficial bacteria. Human lactoferrin (effera™) has been shown in a randomized trial to maintain microbial diversity and support beneficial taxa while preserving community structure (PMID 37376017).
What makes kēpos different for gut barrier support?
kēpos combines kpHMO™ — its proprietary HMO ingredient designed and owned exclusively by kēpos to mirror the full oligosaccharide spectrum of human breast milk — with effera™ recombinant human lactoferrin. Together, these bioactives target gut barrier health through complementary mechanisms: HMOs support tight junction proteins and beneficial microbiota; human lactoferrin enhances occludin expression and preserves microbial diversity. Learn more about kēpos →
This article is for informational purposes only and does not constitute medical advice. kēpos products are not intended to diagnose, treat, cure, or prevent any disease.
